ASR Vermogensbeheer N.V. Purchases Shares of 159,749 IQVIA Holdings Inc. (NYSE:IQV)

Key Points

• ASR Vermogensbeheer N.V. has made a significant investment of $28.16 million in IQVIA Holdings Inc., acquiring 159,749 shares, which accounts for 0.09% of the company's total shares.
• Analysts have a consensus rating of "Moderate Buy" for IQVIA, with a target price averaging $228.62, indicating strong future growth expectations.
• In the latest earnings report, IQVIA surpassed expectations by posting an EPS of $2.81, with a revenue of $4.02 billion for the quarter, marking a 5.3% increase year-over-year.

ASR Vermogensbeheer N.V. acquired a new stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 159,749 shares of the medical research company's stock, valued at approximately $28,162,000. ASR Vermogensbeheer N.V. owned about 0.09% of IQVIA as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of IQV. Continuum Advisory LLC raised its holdings in shares of IQVIA by 3.7% during the fourth quarter. Continuum Advisory LLC now owns 1,803 shares of the medical research company's stock valued at $354,000 after acquiring an additional 64 shares during the period. Ballentine Partners LLC raised its holdings in shares of IQVIA by 4.9% during the first quarter. Ballentine Partners LLC now owns 1,477 shares of the medical research company's stock valued at $260,000 after acquiring an additional 69 shares during the period. ST Germain D J Co. Inc. raised its holdings in shares of IQVIA by 66.1% during the first quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock valued at $34,000 after acquiring an additional 76 shares during the period. Nemes Rush Group LLC raised its holdings in shares of IQVIA by 15.0% during the first quarter. Nemes Rush Group LLC now owns 621 shares of the medical research company's stock valued at $109,000 after acquiring an additional 81 shares during the period. Finally, Quadrant Capital Group LLC raised its holdings in shares of IQVIA by 10.7% during the fourth quarter. Quadrant Capital Group LLC now owns 928 shares of the medical research company's stock valued at $182,000 after acquiring an additional 90 shares during the period. 89.62% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on IQV. UBS Group boosted their price target on shares of IQVIA from $185.00 to $225.00 and gave the company a "buy" rating in a report on Wednesday, July 23rd. Cowen reaffirmed a "buy" rating on shares of IQVIA in a research report on Wednesday, July 23rd. JPMorgan Chase & Co. lowered their price objective on shares of IQVIA from $232.00 to $177.00 and set an "overweight" rating on the stock in a research report on Monday, May 19th. Citigroup reaffirmed a "neutral" rating on shares of IQVIA in a research report on Thursday, May 22nd. Finally, Evercore ISI boosted their price objective on shares of IQVIA from $170.00 to $180.00 and gave the company an "outperform" rating in a research report on Wednesday, July 9th. Seven equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $228.62.

IQVIA Stock Performance

Shares of IQVIA stock traded up $1.03 on Friday, reaching $179.98. The stock had a trading volume of 877,737 shares, compared to its average volume of 2,400,431. The business's 50-day moving average price is $166.23 and its two-hundred day moving average price is $169.45. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.84 and a current ratio of 0.84. IQVIA Holdings Inc. has a fifty-two week low of $134.65 and a fifty-two week high of $252.88. The stock has a market cap of $30.60 billion, a P/E ratio of 26.05, a price-to-earnings-growth ratio of 1.96 and a beta of 1.30.

IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share for the quarter, topping analysts' consensus estimates of $2.77 by $0.04. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The business had revenue of $4.02 billion during the quarter, compared to analysts' expectations of $3.96 billion. During the same period in the previous year, the company earned $2.64 earnings per share. IQVIA's revenue for the quarter was up 5.3% on a year-over-year basis. On average, sell-side analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Insider Buying and Selling at IQVIA

In related news, insider Keriann Cherofsky sold 549 shares of the company's stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $191.53, for a total transaction of $105,149.97. Following the completion of the transaction, the insider directly owned 2,910 shares in the company, valued at $557,352.30. This represents a 15.87% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Eric Sherbet sold 5,800 shares of the company's stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the transaction, the insider owned 27,178 shares of the company's stock, valued at approximately $5,165,178.90. The trade was a 17.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.60% of the stock is owned by corporate insiders.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.